Inotek raises $21m for new glaucoma candidate
This article was originally published in Scrip
Executive Summary
Glaucoma treatment developer Inotek Pharmaceuticals has raised $21m from its existing investors. The cash will be used to advance Inotek's lead product, trabodenoson, a novel eye drop that increases aqueous fluid outflow via the eye's trabecular meshwork, through Phase II studies.